Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

215
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
215
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

252
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
252
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

928
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
928
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

760
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
760
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

796
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
796

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inflammatory biomarkers relationship with major adverse cardiovascular events and hypertensive-mediated organ damage, in subjects without established cardiovascular disease.

American journal of preventive cardiology·2026
Same author

SGLT2 Inhibitors in Elderly Patients: Clinical Perspectives from Metabolic and Cardiorenal Protection to Implementation.

Journal of clinical medicine·2026
Same author

[Ranolazine: established indications and emerging therapeutic potential].

Giornale italiano di cardiologia (2006)·2026
Same author

[Green paper ANMCO: Environmental sustainability in cardiology: a shared commitment of healthcare professionals].

Giornale italiano di cardiologia (2006)·2026
Same author

Diagnostic and therapeutic inertia for LDL cholesterol management of consecutively verified patients with acute myocardial infarction.

European journal of internal medicine·2026
Same author

Integrating Cardiopulmonary Exercise Testing, Stress Echocardiography and Near-Infrared Spectroscopy for Multimodal Assessment of Exercise Intolerance: A Narrative Review.

Healthcare (Basel, Switzerland)·2026

Related Experiment Video

Updated: Jan 15, 2026

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

1.3K

Home Inotropes in Advanced Heart Failure: A Practical Review.

Paolo Manca1,2, Maria Vittoria Matassini2,3, Luca Fazzini4

  • 1Department of Clinical Cardiology and Heart Failure, Mediterranean Institute for Transplantation and Advanced Specialized Therapies, ISMETT IRCCS, 90121 Palermo, Italy.

Journal of Clinical Medicine
|October 16, 2025
PubMed
Summary
This summary is machine-generated.

Home inotropes can improve quality of life and reduce hospitalizations for advanced heart failure (AdHF) patients. This review explores their use in stabilizing patients awaiting advanced therapies or for palliative care.

Keywords:
advanced heart failureheart transplanthome inotropespalliative care

More Related Videos

Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption
12:43

Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption

Published on: August 16, 2016

20.9K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.8K

Related Experiment Videos

Last Updated: Jan 15, 2026

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

1.3K
Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption
12:43

Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption

Published on: August 16, 2016

20.9K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.8K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Advanced heart failure (AdHF) presents significant morbidity and mortality challenges.
  • Current life-prolonging options like heart transplant (HT) and left ventricular assist devices (LVAD) are limited to a minority of patients.
  • Long waiting times for HT further complicate management.

Purpose of the Study:

  • To review the current literature on the role of home inotropic therapy in managing AdHF.
  • To emphasize evidence on commonly used agents, administration considerations, and utilization patterns.
  • To identify literature gaps and suggest future research directions.

Main Methods:

  • Comprehensive literature review of home-based inotropic therapy in AdHF.
  • Analysis of current evidence on inotropic agents, practical administration, and clinical application.
  • Synthesis of findings to address management strategies and future research needs.

Main Results:

  • Home inotropes offer a potential strategy to enhance quality of life and decrease hospitalizations in AdHF.
  • These therapies can stabilize patients eligible for HT or LVAD, and serve palliative roles.
  • Evidence on specific agents, administration, and optimal utilization requires further investigation.

Conclusions:

  • Home inotropic therapy presents a viable option for improving outcomes in select advanced heart failure patients.
  • Further research is needed to optimize the use of home inotropes and expand therapeutic options.
  • Addressing current literature gaps will enhance management strategies for AdHF.